|
1.
|
Peifer M, McCrea PD, Green KJ, Wieschaus E
and Gumbiner BM: The vertebrate adhesive junction proteins
beta-catenin and plakoglobin and the Drosophila segment
polarity gene armadillo form a multigene family with similar
properties. J Cell Biol. 118:681–691. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Zhurinsky J, Shtutman M and Ben-Ze’ev A:
Plakoglobin and beta-catenin: protein interactions, regulation and
biological roles. J Cell Sci. 113:3127–3139. 2000.PubMed/NCBI
|
|
3.
|
Barker N and Clevers H: Catenins, Wnt
signaling and cancer. Bioessays. 22:961–965. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Zhurinsky J, Shtutman M and Ben-Ze’ev A:
Differential mechanisms of LEF/TCF family-dependent transcriptional
activation by beta-catenin and plakoglobin. Mol Cell Biol.
20:4238–4252. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Miravet S, Piedra J, Miro F, Itarte E,
Garcia de Herreros A and Dunach M: The transcriptional factor Tcf-4
contains different binding sites for beta-catenin and plakoglobin.
J Biol Chem. 277:1884–1891. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Aktary Z and Pasdar M: Plakoglobin: role
in tumorigenesis and metastasis. Int J Cell Biol. 2012:1895212012.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Sadot E, Simcha I, Iwai K, Ciechanover A,
Geiger B and Ben-Ze’ev A: Differential interaction of plakoglobin
and beta-catenin with the ubiquitin-proteasome system. Oncogene.
19:1992–2001. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Simcha I, Geiger B, Yehuda-Levenberg S,
Salomon D and Ben-Ze’ev A: Suppression of tumorigenicity by
plakoglobin: an augmenting effect of N-cadherin. J Cell Biol.
133:199–209. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Parker HR, Li Z, Sheinin H, Lauzon G and
Pasdar M: Plakoglobin induces desmosome formation and epidermoid
phenotype in N-cadherin-expressing squamous carcinoma cells
deficient in plakoglobin and E-cadherin. Cell Motil Cytoskeleton.
40:87–100. 1998. View Article : Google Scholar
|
|
10.
|
Winn RA, Bremnes RM, Bemis L, et al:
gamma-catenin expression is reduced or absent in a subset of human
lung cancers and re-expression inhibits transformed cell growth.
Oncogene. 21:7497–7506. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Mukhina S, Mertani HC, Guo K, Lee KO,
Gluckman PD and Lobie PE: Phenotypic conversion of human mammary
carcinoma cells by autocrine human growth hormone. Proc Natl Acad
Sci USA. 101:15166–15171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Rieger-Christ KM, Ng L, Hanley RS, et al:
Restoration of plakoglobin expression in bladder carcinoma cell
lines suppresses cell migration and tumorigenic potential. Br J
Cancer. 92:2153–2159. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Pan H, Gao F, Papageorgis P, Abdolmaleky
HM, Faller DV and Thiagalingam S: Aberrant activation of
gamma-catenin promotes genomic instability and oncogenic effects
during tumor progression. Cancer Biol Ther. 6:1638–1643. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kolligs FT, Kolligs B, Hajra KM, et al:
gamma-catenin is regulated by the APC tumor suppressor and its
oncogenic activity is distinct from that of beta-catenin. Genes
Dev. 14:1319–1331. 2000.PubMed/NCBI
|
|
15.
|
Hazlehurst LA, Bewry NN, Nair RR and
Pinilla-Ibarz J: Signaling networks associated with
BCR-ABL-dependent transformation. Cancer Control. 16:100–107.
2009.PubMed/NCBI
|
|
16.
|
Quintas-Cardama A and Cortes J: Molecular
biology of bcr-abl1-positive chronic myeloid leukemia. Blood.
113:1619–1630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Muller-Tidow C, Steffen B, Cauvet T, et
al: Translocation products in acute myeloid leukemia activate the
Wnt signaling pathway in hematopoietic cells. Mol Cell Biol.
24:2890–2904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Zhao C, Blum J, Chen A, et al: Loss of
beta-catenin impairs the renewal of normal and CML stem cells in
vivo. Cancer Cell. 12:528–541. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Coluccia AM, Vacca A, Dunach M, et al:
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through
its tyrosine phosphorylation. EMBO J. 26:1456–1466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Kim YM, Ma H, Oehler VG, et al: The gamma
catenin/CBP complex maintains survivin transcription in
beta-catenin deficient/depleted cancer cells. Curr Cancer Drug
Targets. 11:213–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Yuan Y, Niu CC, Deng G, et al: The
Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt
signaling in K562 cells. Int J Mol Med. 27:63–69. 2011.PubMed/NCBI
|
|
22.
|
He TC, Sparks AB, Rago C, et al:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Shtutman M, Zhurinsky J, Simcha I, et al:
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.
Proc Natl Acad Sci USA. 96:5522–5527. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Zhang T, Otevrel T, Gao Z, Ehrlich SM,
Fields JZ and Boman BM: Evidence that APC regulates survivin
expression: a possible mechanism contributing to the stem cell
origin of colon cancer. Cancer Res. 61:8664–8667. 2001.
|
|
25.
|
de Groot RP, Raaijmakers JA, Lammers JW
and Koenderman L: STAT5-dependent cyclinD1 and Bcl-xL expression in
Bcr-Abl-transformed cells. Mol Cell Biol Res Commun. 3:299–305.
2000.PubMed/NCBI
|
|
26.
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.
|
|
27.
|
Gaiger A, Henn T, Horth E, et al: Increase
of bcr-abl chimeric mRNA expression in tumor cells of patients with
chronic myeloid leukemia precedes disease progression. Blood.
86:2371–2378. 1995.PubMed/NCBI
|
|
28.
|
Sawyers CL, Callahan W and Witte ON:
Dominant negative MYC blocks transformation by ABL oncogenes. Cell.
70:901–910. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Afar DE, McLaughlin J, Sherr CJ, Witte ON
and Roussel MF: Signaling by ABL oncogenes through cyclin D1. Proc
Natl Acad Sci USA. 92:9540–9544. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Williamson L, Raess NA, Caldelari R, et
al: Pemphigus vulgaris identifies plakoglobin as key suppressor of
c-Myc in the skin. EMBO J. 25:3298–3309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Diamond JM and Melo JV: Mechanisms of
resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma. 52(Suppl
1): S12–S22. 2011. View Article : Google Scholar
|
|
32.
|
Wang Z, Sampath J, Fukuda S and Pelus LM:
Disruption of the inhibitor of apoptosis protein survivin
sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Cancer Res. 65:8224–8232. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Amarante-Mendes GP, McGahon AJ, Nishioka
WK, Afar DE, Witte ON and Green DR: Bcl-2-independent
Bcr-Abl-mediated resistance to apoptosis: protection is correlated
with up regulation of Bcl-xL. Oncogene. 16:1383–1390. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Dusek RL, Godsel LM, Chen F, et al:
Plakoglobin deficiency protects keratinocytes from apoptosis. J
Invest Dermatol. 127:792–801. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Salomon D, Sacco PA, Roy SG, et al:
Regulation of beta-catenin levels and localization by
overexpression of plakoglobin and inhibition of the
ubiquitin-proteasome system. J Cell Biol. 139:1325–1335. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Li L, Chapman K, Hu X, Wong A and Pasdar
M: Modulation of the oncogenic potential of beta-catenin by the
subcellular distribution of plakoglobin. Mol Carcinog. 46:824–838.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Kodama S, Ikeda S, Asahara T, Kishida M
and Kikuchi A: Axin directly interacts with plakoglobin and
regulates its stability. J Biol Chem. 274:27682–27688. 1999.
View Article : Google Scholar : PubMed/NCBI
|
